Archives

by in
Entry Author Date Location
Shire Finds Big Value in Rare Diseases, and a Strong Growth Path for its Boston Unit 05/12/11 New York
Zacharon Nabs $210M Deal With Pfizer to Tackle Orphan Diseases 04/07/11 San Diego
Synageva Grabs $25M for Rare Diseases Drug Pipeline 03/21/11 Boston
Edimer, Third Rock’s Bet on Rare Diseases, Aims to Begin First Human Tests 03/15/11 Boston
Report: Genzyme Chief Could Reap $221.2M in Sanofi Deal 03/08/11 Boston
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche 03/03/11 Boston
NeuroPhage Nets $12.4M to Tackle Alzheimer’s and Other Brain Disorders 03/01/11 Boston
Genzyme Rival Fails to Get FDA Approval 02/25/11 Boston
Alexion Pharma Gobbles Up Taligen in $111M Buyout 01/31/11 Boston
Genzyme to Let Diagnostics Unit Loose for $265M 11/18/10 Boston
PerkinElmer Expects to Make Acquisitions After $500M Business Sale: CEO Talks Boston-Area Talent and Growth in Software, Imaging 09/13/10 Boston
VMware Makes Two Acquisitions, Mascoma Picks Up SunOpta Unit, Vela Gets $6M, & More Boston-Area Deals News 09/08/10 Boston
PerkinElmer Sells Unit for $500M, Aveo Stock Climbs, Pfizer Buys FoldRx, & More Boston-Area Life Sciences News 09/03/10 Boston
Pfizer Gobbles FoldRx in Big Pharma’s Latest Rare Disease Play in Boston Area 09/01/10 Boston
Taligen Collects $10M For Focus on Rare Diseases 08/23/10 Boston
Xconomy Readers Set $20B Pricetag on Genzyme—Is That Too Rich for Sanofi-Aventis? 07/29/10 Boston
How Much Would You Pay for Genzyme? 07/26/10 Boston
Genzyme Gets FDA Nod for Pompe Drug 05/25/10 Boston
Cooking with the Genzyme Recipe: New Players Funding Rare Disease Drugs in Boston 04/12/10 Boston
Page 2 of 2 « previous page